Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
Rhea-AI Summary
Liquidia (Nasdaq:LQDA) announced its inclusion in the S&P SmallCap 600 Index, effective before market open on June 22, 2026. The index tracks 600 U.S. small-cap companies chosen by S&P Dow Jones Indices using market cap, liquidity, public float, and profitability criteria.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Inclusion in the S&P SmallCap 600 Index effective June 22, 2026
- Meets S&P criteria for market cap, liquidity, float, and profitability
Negative
- None.
News Market Reaction – LQDA
On the day this news was published, LQDA gained 4.38%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.6% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $247M to the company's valuation, bringing the market cap to $5.89B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference appearance | Neutral | +3.2% | Jefferies healthcare conference fireside chat and webcast availability. |
| May 11 | Earnings results | Positive | +25.6% | Strong Q1 2026 results driven by YUTREPIA product sales and profitability. |
| May 06 | Investor conferences | Neutral | +5.0% | Participation in May investor conferences with management presentations and meetings. |
| May 04 | Earnings date notice | Neutral | +0.9% | Announcement of Q1 2026 earnings release date and webcast details. |
| Apr 07 | Investor conferences | Neutral | -0.8% | Planned April investor conferences with one-on-one meetings and webcasted chat. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially strong earnings and investor events, has generally coincided with positive price reactions.
Over the past few months, Liquidia’s news flow has centered on investor outreach and financial strength. The company reported strong Q1 2026 results on May 11, 2026, with that earnings release followed by a 25.6% gain. Multiple conference and presentation announcements on April 7, 2026, May 6, 2026, and May 27, 2026 saw smaller but mostly positive moves. Today’s S&P SmallCap 600 inclusion highlights further corporate validation on top of these prior milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.
Introduced in 1994, the S&P SmallCap 600 is a widely followed benchmark of 600 U.S. small-cap companies selected by S&P Dow Jones Indices based on market capitalization, liquidity, shares available for public trading, and profitability criteria.
Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Inclusion in the S&P SmallCap 600 is a meaningful marker of how far Liquidia has come, and it is a credit to the entire team. It reflects the discipline and execution behind our progress and the foundation we have built through our commitment to patients, innovation and operational excellence. We are focused on the opportunities ahead as we continue our work to revolutionize care for patients with challenging respiratory and vascular diseases.”
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® technology. PRINT enabled the development of YUTREPIA® (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding the timing and anticipated impact of the Company’s inclusion in the S&P SmallCap 600 Index, potential enhanced visibility within the investment community, as well as the Company’s strategy, operating priorities and future performance, including statements regarding market capitalization, liquidity, financial viability and long-term value creation, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “will,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
Investors:
Jason Adair
Chief Business Officer
919.328.4350
Media Contact:
media@liquidia.com
